Home Icon

Loading, Please Wait...

Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease

987 Days ago

REDWOOD CITY, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will conduct one-on-one investor meetings at the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease, being held September 26-27, 2018, in New York, NY.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, is currently being evaluated in a Phase III clinical development program.

For more information, please visit www.soleno.life

CONTACT:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

We Are Diffrent
Is your business listed correctly on America’s largest city directory network of 1,000 portals? Find your City Portal